40 / 50
Overview of NCCN / ASCO / MASCC-ESMO guidelines
for delayed nausea and vomiting
Emetic risk groups
Antiemetics
High (non-AC)
High: anthracycline +
cyclophosphamide (AC)
Carboplatin
b
Moderate
c
Low
-
DEX
DEX**
±
OLA*
±
OLA*
a
NK1 RA (aprepitant 80 mg) only if aprepitant 125 mg was used on Day 1. Other NK1 RAs, netupitant, rolapitant, aprepitant 165 mg or fosaprepitant 150 mg do
not need repeat doses.
* The addition of OLA is recommended in HEC by ASCO, is one possible option in HEC and MEC by NCCN and only when nausea is an issue by MASCC/ESMO.
** DEX is recommended in AC by NCCN and, If APR on D1, APR or DEX by MASCC/ESMO.
b
Carboplatin: DEX is recommended only by NCCN over AUC >4
c Only for regimens with known delayed CINV potential by MASCC/ESMO and ASCO.
NK
1
RA
a
NK
1
RA
a
+
NK
1
RA
a
+
OLA*
OLA*
±
DEX
±
1. Roila F. et al. Ann Oncol. 2016 Sep;27(suppl 5):v119-v133. MASCC/ESMO Antiemetic Guideline 2016 V.1.2. Available at:
http://www.mascc.org/; 2.
NCCN: National Comprehensive Cancer Network; NCCN
Clinical Practice Guidelines in Oncology; Version 3.2018. Available at:
www.nccn.org; 3.
Hesketh P. J. et al. J Clin Oncol. 2017 Oct 1;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789. Epub 2017 Jul 31.
+
DEX**